Efficacy of ETB-F01, Heat-Killed <i>Akkermansia muciniphila</i> Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial.

ABSTRACT: Respiratory symptoms are prevalent in the general population, and they are associated with a decline in lung function and increased mortality. The gut-lung connection suggests intestinal dysbiosis may impact lung diseases, with Akkermansia muciniphila showing promise in regulating extraintestinal diseases. However, its application in patients with respiratory symptoms lacks clinical trial evidence. In this randomized, double-blind trial, ETB-F01, containing heat-killed A. muciniphila strain EB-AMDK19, was compared with a placebo in patients experiencing respiratory symptoms for 4 to 12 weeks. The primary outcome was improvement in Breathlessness, Cough, and Sputum Scale (BCSS) score over 12 weeks. Secondary outcomes included lung function, fractional exhaled nitric oxide (FeN

SUBMITTER: Lee HW 

PROVIDER: S-EPMC11643724 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature